InnoCore Pharmaceuticals Overview
- Year Founded
-
2004
- Status
-
Private
- Employees
-
48
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$1.57M
- Investors
-
1
InnoCore Pharmaceuticals General Information
Description
Developer of long-acting injectable drug delivery formulations designed to help the treatment of chronic diseases. The company utilizes its proprietary drug delivery technology to develop biodegradable sustained-release depots for precisely controlled delivery of therapeutic compounds, enabling doctors to provide optimal treatment that improves the quality of life of patients.
Contact Information
Website
www.innocorepharma.comCorporate Office
- L.J. Zielstraweg 1
- 9713 GX Groningen
- Netherlands
Corporate Office
- L.J. Zielstraweg 1
- 9713 GX Groningen
- Netherlands
InnoCore Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Grant | 01-Jun-2020 | $1.57M | Completed | Generating Revenue |
InnoCore Pharmaceuticals Patents
InnoCore Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3180971-A1 | Long-acting bupivacaine microsphere formulations | Pending | 22-Apr-2020 | ||
| JP-2024091835-A | Long-acting bupivacaine microsphere formulations | Pending | 22-Apr-2020 | ||
| US-20240033221-A1 | Long-acting bupivacaine microsphere formulations | Pending | 22-Apr-2020 | ||
| WO-2021216928-A1 | Long-acting bupivacaine microsphere formulations | Inactive | 22-Apr-2020 | ||
| CA-3179866-A1 | Long-acting apomorphine formulations and injectors for therapeutic delivery of the same | Pending | 10-Apr-2020 | A61K31/485 |
InnoCore Pharmaceuticals Signals
InnoCore Pharmaceuticals Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Gates Foundation | Not-For-Profit Venture Capital |
InnoCore Pharmaceuticals Investments & Acquisitions (2)
InnoCore Pharmaceuticals’s most recent deal was a Merger/Acquisition with InGell. The deal was made on 01-Dec-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| InGell | 01-Dec-2017 | Merger/Acquisition | Drug Delivery | ||
| InGell | 01-Jan-2015 | Corporate | Drug Delivery |
InnoCore Pharmaceuticals FAQs
-
When was InnoCore Pharmaceuticals founded?
InnoCore Pharmaceuticals was founded in 2004.
-
Where is InnoCore Pharmaceuticals headquartered?
InnoCore Pharmaceuticals is headquartered in Groningen, Netherlands.
-
What is the size of InnoCore Pharmaceuticals?
InnoCore Pharmaceuticals has 48 total employees.
-
What industry is InnoCore Pharmaceuticals in?
InnoCore Pharmaceuticals’s primary industry is Drug Delivery.
-
Is InnoCore Pharmaceuticals a private or public company?
InnoCore Pharmaceuticals is a Private company.
-
What is InnoCore Pharmaceuticals’s current revenue?
The current revenue for InnoCore Pharmaceuticals is .
-
Who are InnoCore Pharmaceuticals’s investors?
Gates Foundation has invested in InnoCore Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process